Form D · Other Technology

LevitasBio, Inc.

Menlo Park, CA · CIK 0001713509

Offering snapshot reported Apr 10, 2024 · SEC filing

Reported sold
$11.8M
Offering amount: $25.1M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 28, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 10, 2024Initial$11,759,181No comparison3SEC filing
Oct 26, 2022Initial$34,999,997No comparison4SEC filing
Jan 15, 2021Initial$19,011,644No comparison5SEC filing
Aug 3, 2017Initial$8,000,001No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-510176

Source: Form D, filed Apr 10, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Xiangmin Cui Director
Utkan Demirci Director
Sandy Gardiner Director
Greg Herrema Director
Paul Meister Director
Martin Pieprzyk Director, Executive
Lars Steinmetz Director
Steve Tablak Director
Victor Tong Director
Victor E. Tong, Jr. Director
Zheng Wang Director

Issuer details

Industry: Other Technology (See others in industry)

Address:
1505 Adams Drive, Suite D
Menlo Park, CA, 94025